Antibodies against alpha-synuclein reduce oligomerization in living cells.
Recent research implicates soluble aggregated forms of α-synuclein as neurotoxic species with a central role in the pathogenesis of Parkinson's disease and related disorders. The pathway by which α-synuclein aggregates is believed to follow a step-wise pattern, in which dimers and smaller oligo...
Guardado en:
Autores principales: | Thomas Näsström, Susana Gonçalves, Charlotte Sahlin, Eva Nordström, Valentina Screpanti Sundquist, Lars Lannfelt, Joakim Bergström, Tiago F Outeiro, Martin Ingelsson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2011
|
Materias: | |
Acceso en línea: | https://doaj.org/article/36540fddbde747e09f645e1c2d74f401 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
ABBV-0805, a novel antibody selective for soluble aggregated α-synuclein, prolongs lifespan and prevents buildup of α-synuclein pathology in mouse models of Parkinson's disease
por: Eva Nordström, et al.
Publicado: (2021) -
(Poly)phenol-digested metabolites modulate alpha-synuclein toxicity by regulating proteostasis
por: Diana Macedo, et al.
Publicado: (2018) -
Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease
por: Luis M. A. Oliveira, et al.
Publicado: (2021) -
The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models
por: Rachel Kelly, et al.
Publicado: (2021) -
Alpha-Synuclein and Cognitive Decline in Parkinson Disease
por: Tian-Sin Fan, et al.
Publicado: (2021)